AVASTINĀ®
(Bevacizumab)
Documentation
Patented
Approved 2004
FDA Letter
FDA Label
Full Sequence
Brief Summary
Function Type: Antagonist
Target: VEGF-A
Indication Category: Cancer
Patented
Approved 2004
FDA Letter
FDA Label
Full Sequence
Function Type: Antagonist
Target: VEGF-A
Indication Category: Cancer